Species |
Mouse |
Protein Construction |
GRO-α (Ala25-Lys96) Accession # P12850 |
|
Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
Biological Activity |
Active at 10.0 ng/ml, measured in a tube formation assay using HUVEC cells. |
Expression System |
CHO |
Apparent Molecular Weight |
5~7 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Lyophilized after extensive dialysis against PBS. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Target Background |
GRO-α/KC/CXCL1 coded by CXCL1 gene at chromosome 5 is approximately 63% identity to that of mouse MIP2. KC is also approximately 60% identical to the human GROs. Mouse KC is a potent neutrophil attractant and activator. The functional receptor for KC has been identified as CXCR2. Based on the pattern of KC expression in a number of inflammatory disease models, KC appears to have an important role in inflammation. KC was found to be involved in monocyte arrest on atherosclerotic endothelium and may also play a pathophysiological role in Alzheimer’s disease. |
Synonyms |
Growth Regulated Protein/Melanoma Growth Stimulatory Activity; GRO α; MGSA α; CXCL1; NAP-3; GRO1; KC (murine); CINC (rat) |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.